BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 19810774)

  • 21. Imatinib-induced Stevens-Johnsons syndrome.
    Jha P; Himanshu D; Jain N; Singh AK
    BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23349042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
    Santachiara R; Maffei R; Martinelli S; Arcari A; Piacentini F; Trabacchi E; Alfieri P; Ferrari A; Leonardi G; Luppi G; Longo G; Vallisa D; Marasca R; Torelli G
    Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib mesylate, the first molecularly targeted gene suppressor.
    Pindolia VK; Zarowitz BJ
    Pharmacotherapy; 2002 Oct; 22(10):1249-65. PubMed ID: 12389876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
    Hochhaus A; Kantarjian HM; Baccarani M; Lipton JH; Apperley JF; Druker BJ; Facon T; Goldberg SL; Cervantes F; Niederwieser D; Silver RT; Stone RM; Hughes TP; Muller MC; Ezzeddine R; Countouriotis AM; Shah NP
    Blood; 2007 Mar; 109(6):2303-9. PubMed ID: 17138817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. STI571 as a targeted therapy for CML.
    O'Dwyer ME; Mauro MJ; Druker BJ
    Cancer Invest; 2003 Jun; 21(3):429-38. PubMed ID: 12901289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imatinib Mesylate.
    Waller CF
    Recent Results Cancer Res; 2018; 212():1-27. PubMed ID: 30069623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202).
    Nishida T; Shirao K; Sawaki A; Koseki M; Okamura T; Ohtsu A; Sugiyama T; Miyakawa K; Hirota S
    Int J Clin Oncol; 2008 Jun; 13(3):244-51. PubMed ID: 18553235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
    Hochhaus A
    Ann Hematol; 2004; 83 Suppl 1():S65-6. PubMed ID: 15124676
    [No Abstract]   [Full Text] [Related]  

  • 29. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
    Kantarjian HM; Cortes J; O'Brien S; Giles FJ; Albitar M; Rios MB; Shan J; Faderl S; Garcia-Manero G; Thomas DA; Resta D; Talpaz M
    Blood; 2002 May; 99(10):3547-53. PubMed ID: 11986206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The development and application of imatinib.
    Jones RL; Judson IR
    Expert Opin Drug Saf; 2005 Mar; 4(2):183-91. PubMed ID: 15794712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial treatment for patients with CML.
    Goldman JM
    Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia].
    Grzybowska-Izydorczyk O; Góra-Tybor J; Robak T
    Postepy Hig Med Dosw (Online); 2006; 60():490-7. PubMed ID: 17013368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A rare complication of imatinib mesylate therapy: drug-induced pneumonitis].
    Stakhina OV; Turkina AG; Kostina IE; Kochkareva IuB
    Ter Arkh; 2010; 82(2):59-61. PubMed ID: 20387680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.
    Kantarjian HM; Talpaz M; Giles F; O'Brien S; Cortes J
    Ann Intern Med; 2006 Dec; 145(12):913-23. PubMed ID: 17179059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New strategies in controlling drug resistance.
    Frame D
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):13-7. PubMed ID: 17970610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imatinib mesylate.
    Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
    [No Abstract]   [Full Text] [Related]  

  • 37. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
    Cortes JE; Talpaz M; Giles F; O'Brien S; Rios MB; Shan J; Garcia-Manero G; Faderl S; Thomas DA; Wierda W; Ferrajoli A; Jeha S; Kantarjian HM
    Blood; 2003 May; 101(10):3794-800. PubMed ID: 12560227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
    Wu J; Meng F; Kong LY; Peng Z; Ying Y; Bornmann WG; Darnay BG; Lamothe B; Sun H; Talpaz M; Donato NJ
    J Natl Cancer Inst; 2008 Jul; 100(13):926-39. PubMed ID: 18577747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
    Demetri GD
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful pregnancy in a patient with chronic myeloid leukemia under treatment with imatinib.
    Tsuzuki M; Inaguma Y; Handa K; Hasegawa A; Yamamoto Y; Watanabe M; Mizuta S; Maruyama F; Okamoto M; Emi N
    Intern Med; 2009; 48(16):1433-5. PubMed ID: 19687593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.